Activation of Natural Killer Cells in Patients with Chronic Bone and Joint Infection due to Staphylococci Expressing or Not the Small Colony Variant Phenotype. (3rd March 2014)

• Record Type: Journal Article
• Authors: Viel, Sébastien; Rouzaire, Paul; Laurent, Frédéric; Walzer, Thierry; Bienvenu, Jacques; Valour, Florent; Chidiac, Christian; Ferry, Tristan; Group, The Lyon BJI Study
• Other Names: Robak Tadeusz Academic Editor.
• Is Part Of: International journal of chronic diseases. Volume 2014(2014)
• Publication Date: 2014-03-03
• Subjects: Chronic diseases -- Periodicals; Chronic Disease; Chronic diseases; Periodicals; Periodicals; Electronic journals; Fulltext; Internet Resources; Periodicals; 616.044
• DOI: 10.1155/2014/280653
• Languages: English
• ISSNs: 2356-6981

Abstract

Abstract : Chronic bone and joint infections (BJI) are devastating diseases. Relapses are frequently observed, as some pathogens, especially staphylococci, can persist intracellularly by expressing a particular phenotype called small colony variant (SCV). As natural killer (NK) cells are lymphocytes specialized in the killing of host cells infected by intracellular pathogens, we studied NK cells of patients with chronic BJI due to staphylococci expressing or not SCVs (10 patients in both groups). Controls were patients infected with other bacteria without detectable expression of SCVs, and healthy volunteers. NK cell phenotype was evaluated from PBMCs by flow cytometry. Degranulation capacity was evaluated after stimulation with K562 cells in vitro . We found that NK cells were activated in terms of CD69 expression, loss of CD16 and perforin, in all infected patients in comparison with healthy volunteers, independently of the SCV phenotype. Peripheral NK cells in patients with chronic BJI display signs of recent activation and degranulation in vivo in response to CD16-mediated signals, regardless of the type of bacteria involved. This could involve a universal capacity of isolates responsible for chronic BJI to produce undetectable SCVs in vivo, which might be a target of future intervention.